List view / Grid view
4 March 2015 | By The Institute of Cancer Research
Changing the shape of breast cancer cells could make the disease more sensitive to treatments – even driving the body’s own inflammatory response against a tumour – a new study shows...
4 March 2015 | By Domain Therapeutics
Kaldi Pharma granted its first license to CleveXel Pharma, who will develop a preclinical candidate for Parkinson’s disease...
4 March 2015 | By The Northern Health Science Alliance
The NHSA’s ambitious project of establishing an internationally recognised life science and healthcare economy in the North of England has been given a vital boost following funding from HEFCE...
4 March 2015 | By ORYX
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, announced the successful completion of a Phase I/IIa trial of the therapeutic vaccine MicOryx to treat advanced microsatellite instable (MSI-H-) colorectal cancer patients in an open label, single center trial that included 22 patients (UICC stage III or…
4 March 2015 | By Bristol-Myers Squibb Company
Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments; additional tiered double-digit royalties on future sales...
3 March 2015 | By Probiodrug
Strong correlation between QCs and AD pathology in human brain biopsies underlines QC-inhibition as therapeutic approach...
2 March 2015 | By MRC Technology
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease...
27 February 2015 | By The Institute of Cancer Research
Scientists have developed a new test which can predict the survival chances of women with breast cancer by analysing images of ‘hotspots’ where there has been a fierce immune reaction to a tumour...
26 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced data supporting the clinical development of BMS-955176, an investigational component designed to prevent the maturation of HIV-1...
26 February 2015 | By TxCell
TxCell invited to speak at largest US meeting for investors in emerging growth companies...
26 February 2015 | By Roche
Contribution to the treatment of melanoma by personalized healthcare...
26 February 2015 | By MSD
Expansion in treatment options for moderately to severely active disease allows patients access to REMICADE® (infliximab), SIMPONI® (golimumab) and Humira® (adalimumab)...
25 February 2015 | By Oxford Global
Oxford Global are proud to present its 3rd Annual Discovery Chemistry & Drug Design will be on the 8th and 9th of June 2015...
25 February 2015 | By Oxford Global
Oxford Global are proud to present its 16th Annual Drug Discovery Congress will be on the 8th and 9th of June 2015...
25 February 2015 | By Mundipharma
Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets...
